Imaging correlates of behavioral impairments

• Verfasst von: Di Liberto, Valentina [VerfasserIn]
• Verfasst von: van Dijk, R. Maarten [VerfasserIn]
• Verfasst von: Brendel, Matthias [VerfasserIn]
• Verfasst von: Waldron, Ann-Marie [VerfasserIn]
• Verfasst von: Möller, Christina [VerfasserIn]
• Verfasst von: Koska, Ines [VerfasserIn]
• Verfasst von: Seiffert, Isabel Leonie [VerfasserIn]
• Verfasst von: Gualtieri, Fabio [VerfasserIn]
• Verfasst von: Gildehaus, Franz-Josef [VerfasserIn]
• Verfasst von: Ungern-Sternberg, Barbara von [VerfasserIn]
• Verfasst von: Lindner, Magdalena Julia [VerfasserIn]
• Verfasst von: Ziegler, Sibylle [VerfasserIn]
• Verfasst von: Palme, Rupert [VerfasserIn]
• Verfasst von: Hellweg, Rainer [VerfasserIn]
• Verfasst von: Gass, Peter [VerfasserIn]
• Verfasst von: Bartenstein, Peter [VerfasserIn]
• Verfasst von: Potschka, Heidrun [VerfasserIn]
• Titel: Imaging correlates of behavioral impairments
• Titelzusatz: An experimental PET study in the rat pilocarpine epilepsy model
• Verf.angabe: Valentina Di Liberto, R. Maarten van Dijk, Matthias Brendel, Ann-Marie Waldron, Christina Möller, Ines Koska, Isabel Seiffert, Fabio Gualtieri, Franz Josef Gildehaus, Barbara von Ungern-Sternberg, Magdalena Lindner, Sibylle Ziegler, Rupert Palme, Rainer Hellweg, Peter Gass, Peter Bartenstein, Heidrun Potschka
• E-Jahr: 2018
• Jahr: 20 June 2018
• Umfang: 13 S.
• Fussnoten: Gesehen am 28.02.2020
• Titel Quelle: Enthalten in: Neurobiology of disease
• Ort Quelle: [Amsterdam] : Elsevier, 1994
• Jahr Quelle: 2018
• Band/Heft Quelle: 118(2018), Seite 9-21
• ISSN Quelle: 1095-953X
• DOI: doi:10.1016/j.nbd.2018.06.010
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: F-FDG
• Sach-SW: F-MPPF
• Sach-SW: Animal model
• Sach-SW: BDNF
• Sach-SW: Behavior
• Sach-SW: Epilepsy
• Sach-SW: PET
• K10plus-PPN: 1691219894

Abstract

Psychiatric comorbidities are prevalent in patients with epilepsy and greatly contribute to the overall burden of disease. The availability of reliable biomarkers to diagnose epilepsy-associated comorbidities would allow for effective treatment and improved disease management. Due to their non-invasive nature, molecular imaging techniques such as positron emission tomography (PET) are ideal tools to measure pathologic changes. In the current study we investigated the potential of [18F]fluoro-2-deoxy-d-glucose ([18F]FDG) and 2′-methoxyphenyl-(N-2′-pyridinyl)-p-18F-fluoro-benzamidoethylpiperazine ([18F]MPPF) as imaging correlates of neurobehavioral comorbidities in the pilocarpine rat model of epilepsy. Findings from rats with epilepsy revealed a regional reduction in [18F]FDG uptake indicating thalamic hypometabolism. In addition, an increase in septal [18F]MPPF binding was observed in rats with spontaneous recurrent seizures. Both thalamic [18F]FDG and septal [18F]MPPF data proved to correlate with behavioral alterations including decreases in luxury behavior such as burrowing and social interaction, and changes in behavioral patterns in anxiety tests. A correlation with seizure frequency was confirmed for thalamic [18F]FDG data. Moreover, thalamic [18F]FDG and septal [18F]MPPF data exhibited a correlation with brain-derived neurotrophic factor (BDNF) serum concentrations, which were lowered in rats with epilepsy. In conclusion, μPET data from rats with pilocarpine-induced epileptogenesis indicate altered septal 5-HT1A receptor binding. Further research is necessary assessing whether septal 5-HT1A receptor binding may serve as an imaging correlate of neuropsychiatric comorbidities in epilepsy patients and for severity assessment in rodent epilepsy models. In contrast, we obtained evidence that [18F]FDG uptake also reflects the severity of epilepsy and, thus, might not constitute a biomarker with sufficient specificity for psychiatric comorbidities. Evidence has been obtained that BDNF might serve as a peripheral circulatory biomarker. Further experimental and clinical assessment is necessary for validation of the marker candidates.